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ABSTRACT
The blood–brain barrier (BBB), an interface between the systemic circulation
and the nervous system, can be a target of cytokines in inflammatory conditions.
Pro-inflammatory cytokines tumor necrosis factor-a (TNF-a) and interleukin-1b
(IL-1b) induce damage in brain endothelial cells and BBB dysfunction which
contribute to neuronal injury. The neuroprotective effects of a-melanocyte
stimulating hormone (a-MSH) were investigated in experimental models, but there
are no data related to the BBB. Based on our recent study, in which a-MSH reduced
barrier dysfunction in human intestinal epithelial cells induced by TNF-a and IL-1b,
we hypothesized a protective effect of a-MSH on brain endothelial cells. We
examined the effect of these two pro-inflammatory cytokines, and the neuropeptide
a-MSH on a culture model of the BBB, primary rat brain endothelial cells co-
cultured with rat brain pericytes and glial cells. We demonstrated the expression of
melanocortin-1 receptor in isolated rat brain microvessels and cultured brain
endothelial cells by RT-PCR and immunohistochemistry. TNF-a and IL-1b induced
cell damage, measured by impedance and MTT assay, which was attenuated by
a-MSH (1 and 10 pM). The peptide inhibited the cytokine-induced increase in
brain endothelial permeability, and restored the morphological changes in cellular
junctions visualized by immunostaining for claudin-5 and b-catenin. Elevated
production of reactive oxygen species and the nuclear translocation of NF-kB were
also reduced by a-MSH in brain endothelial cells stimulated by cytokines. We
demonstrated for the first time the direct beneficial effect of a-MSH on cultured
brain endothelial cells, indicating that this neurohormone may be protective
at the BBB.
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INTRODUCTION
The neuropeptide a-melanocyte stimulating hormone (a-MSH) belongs to the family
of melanocortins, which are created from pro-opiomelanocortin (Catania et al., 2010).
The a-MSH, a 13 amino acid long peptide hormone, is mainly produced in the
hypothalamic region (Brzoska et al., 2008). Induction of melanogenesis in pigment cells
and immunomodulation are among its main physiological functions (Catania, 2008).
There are five melanocortin receptors (MCRs), from which four, MC1R, MC3R,
MC4R, and MC5R, bind a-MSH (Brzoska et al., 2008). MCRs are G-protein-coupled
and exert their effects via cyclic 3′,5′-adenosine monophosphate (cAMP)-dependent
signaling pathways. The predominant receptor of a-MSH is MC1R, which binds the
neuropeptide with high affinity, and is expressed in both the brain and periphery.
MC1R was demonstrated in several tissues, such as brain, skin, immune system, and
gut (Brzoska et al., 2008).
Melanocortins are evolutionary conserved defense molecules against tissue injury and
bacterial invasion (Catania, 2008). The immunomodulatory and anti-inflammatory
effects of a-MSH are well known and widely investigated. The anti-inflammatory
action of a-MSH was proven in animal models of systemic or local inflammation, like
sepsis, arthritis, uveitis, dermatitis, pancreatitis, and colitis (Brzoska et al., 2008). The
protective effect of a-MSH was also shown in ischemic conditions in the heart (Vecsernye´s
et al., 2003, 2017), retina (Varga et al., 2013), kidney and intestine (Brzoska et al., 2008).
In addition to animal models of gut inflammation (Rajora et al., 1997a), the effects
of a-MSH were examined on cell cultures. Our groups have recently described that
pro-inflammatory cytokines tumor necrosis factor-a (TNF-a) and interleukin-1b
(IL-1b) disrupted the barrier integrity of Caco-2 human intestinal epithelial cells, which
was attenuated by a-MSH via the inhibition of the NF-kB pathway (Va´radi et al., 2017).
In addition to systemic inflammatory conditions, the beneficial effect of a-MSH was
also investigated in models of acute and chronic injuries of the central nervous system
(CNS; Catania, 2008). Treatment with a-MSH was neuroprotective in cerebral ischemia,
traumatic spinal cord injury, kainic acid induced excitotoxic brain damage, and
lipopolysaccharide (LPS)-induced cerebral inflammation in animal studies. One of the
main mechanisms of action of a-MSH is the down-regulation of pro-inflammatory
cytokines TNF-a and/or IL-1b in blood and brain tissue, as it was described in
LPS-induced brain inflammation (Rajora et al., 1997b) and unilateral middle cerebral
artery occlusion (Huang & Tatro, 2002) in mice, and in kainic acid-induced brain damage
in rats (Forslin Aronsson et al., 2007). Studies on cultured astrocytes, neurons, and
microglia revealed that, similarly to the periphery, inhibition of the NF-kB pathway
and downstream blockade of pro-inflammatory cytokine release and nitric oxide
overproduction contribute to the protective effects of a-MSH (Catania, 2008).
Dysfunction of the blood–brain barrier (BBB) has been described in many systemic and
CNS inflammatory diseases (Erickson & Banks, 2018) and plays a central role in the
pathomechanism of many neurological diseases (Zhao et al., 2015; Liebner et al., 2018).
TNF-a and IL-1b are the two most studied major pro-inflammatory cytokines in
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neuroinflammation observed in CNS pathologies (Sochocka, Diniz & Leszek, 2017;
Liebner et al., 2018), and induced by systemic inflammation (Hoogland et al., 2015). The
elevated levels of these two cytokines, confirmed in chronic neurodegenerative diseases
(Sochocka, Diniz & Leszek, 2017), open the BBB (Liebner et al., 2018). TNF-a directly
increases the permeability of the BBB for marker molecules in animal studies (Megyeri
et al., 1992; A´braha´m et al., 1996), as well as in culture models (Deli et al., 1995) and a
similar effect was described for IL-1b in BBB in vitro experiments (for review see
Deli et al., 2005). Since these two pro-inflammatory cytokines are major players in both
systemic and CNS inflammation and induce BBB dysfunction, TNF-a and IL-1b were
selected for our experiments.
A binding site was found on murine brain endothelial cells by radiolabeled a-MSH
(de Angelis et al., 1995), suggesting the presence of MCR(s) at the BBB, but they were not
identified. MCRs expressed on cells of the neurovascular unit could mediate the
neuroprotective actions of melanocortins (Catania, 2008), however, the effects of a-MSH
on the BBB, especially on brain endothelial cells have not been investigated yet.
Therefore, our aim was to investigate the effects of a-MSH peptide on a culture model
of the BBB, its possible protective action against barrier disruption induced by TNF-a
and IL-1b cytokines by measuring cellular viability, permeability for marker molecules,
structure of interendothelial tight junctions, production of reactive oxygen species (ROS)
and the nuclear translocation of NF-kB p65 subunit.
MATERIALS AND METHODS
Materials
All reagents were purchased from Sigma-Aldrich Corporation (subsidiary of Merck KGaA,
Darmstadt, Germany) unless otherwise indicated.
Cell culture
Primary rat brain endothelial cells were isolated from three week-old outbred Wistar
rats (Harlan Laboratories, Indianapolis, IN, USA) as described in our previous paper
(Veszelka et al., 2013). Forebrains were collected in ice-cold sterile phosphate buffered
saline (PBS). After meninges were removed the tissue was cut into 1 mm3 pieces by scalpel
and digested with enzymes (1 mg/ml collagenase type II, and 15 mg/ml deoxyribonuclease
type I; Roche, Basel, Switzerland) in Dulbecco’s modified Eagle medium (DMEM/F12,
Gibco; Life Technologies, Carlsbad, CA, USA) at 37 C for 55 min. Microvessels were
separated from myelin rich fraction by centrifugation in 20% BSA–DMEM gradient
(1,000g, 20 min, three times). The collected vessels were further digested with enzymes
(1 mg/ml collagenase–dispase, and 15 mg/ml deoxyribonuclease type I; Roche, Basel,
Switzerland) in DMEM/F12 at 37 C for 35 min. Brain microvascular endothelial cell
clusters were separated on a 33% continuous Percoll gradient (1,000g, 10 min),
collected, and washed twice in DMEM/F12. Cells were seeded onto Petri dishes
(100 mm; Orange Scientific, Braine-l’Alleud, Belgium) coated with collagen type IV
and fibronectin (100 mg/ml each). Cultures were maintained in DMEM/F12
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supplemented with 15% plasma-derived bovine serum (First Link, Wolverhampton, UK),
5 mg/ml insulin-transferrin-sodium selenite (Pan Biotech, Aidenbach, Germany), 1 ng/ml
basic fibroblast growth factor (Roche, Basel, Switzerland), 100 mg/ml heparin, and
5 mg/ml gentamycin. For the first three days of culture cells were grown in medium
with 3 mg/ml puromycin to eliminate P-glycoprotein negative contaminating cell types
(Perrie`re et al., 2005). When endothelial cells reached 90% confluency, they were
subcultivated for different experiments.
Primary rat brain pericytes were isolated by the same method, except that the second
digestion lasted only for 15 min. After isolation cells were plated onto uncoated dishes and
they were cultured in low-glucose DMEM medium (Gibco, Life Technologies, Carlsbad,
CA, USA) supplemented with 10% FBS (Pan Biotech, Aidenbach, Germany) and
gentamycin. No puromycin was applied. Pericytes were used at third passage for
experiments.
Primary rat glial cells were isolated from one-day-old Wistar rats. After meninges were
removed brain tissue was mechanically dissociated by a syringe equipped with a long
needle. The tissue homogenate was filtered through a nylon mesh (40 mm; Millipore,
Billerica, MA, USA) to remove large tissue pieces and vessels. Cell clusters in the filtrate
were plated onto uncoated 75 cm2 flasks (TPP, Trasadingen, Switzerland), cultured until
90% confluency in DMEM containing 10% FBS (Lonza, Basel, Switzerland) and
gentamycin. For the BBB co-culture model glial cells were passaged at a cell number of 5
104 cells/well for 12-well plates (Corning Costar, Corning, NY, USA) and cultured for two
weeks before use. Confluent glia cultures contained 90% of GFAP immunopositive
astroglia, and 10 % CD11b immunopositive microglia.
To induce BBB characteristics brain endothelial cells were co-cultured with brain
pericytes and glial cells (Nakagawa et al., 2009) using 12-well format tissue culture
inserts (Transwell clear, polyester membrane, 0.4 mm pore size, 1.12 cm2 surface; Corning
Costar, Corning, NY, USA). Rat pericytes (1.5  104 cells/cm2) were subcultivated to
the bottom side of the insert membranes and brain endothelial cells (7.5  104 cells/cm2)
were passaged to the upper side of the collagen type IV and fibronectin coated inserts.
Both compartments received endothelial culture medium. After two days of co-culture,
brain endothelial cells reached confluency and 550 nM hydrocortisone was added to
the culture medium to tighten junctions (Walter et al., 2015). Before experiments 250 mM
8-(4-chlorophenylthio)-cAMP and 17.5 mM Ro 20-1724 (Roche, Basel, Switzerland)
were added to the endothelial cells for 24 h to tighten junctions and elevate resistance
(Deli et al., 2005; Perrie`re et al., 2005).
Treatments
The neuropeptide a-MSH (Mw. 1664.8 Da) was tested at 1 pM to 1 mM concentrations.
The use of cytokine cocktails is common in CNS culture studies (Sochocka, Diniz & Leszek,
2017). We have also used a combination of TNF-a (50 ng/ml) and IL-1b (25 ng/ml)
on intestinal epithelial cells in our previous study (Va´radi et al., 2017). Based on this study,
we have tested a combination of the pro-inflammatory cytokines TNF-a (10–50 ng/ml)
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and IL-1b (10–25 ng/ml) for 24 h to induce damage in brain endothelial cells. The
control group received culture medium only.
Total RNA isolation and RT-PCR
Brain microvessels were isolated from adult rat brains as published earlier (Veszelka et al.,
2007). For receptor expression analysis total RNA was isolated from isolated brain
microvessels and brain endothelial cells by TRI Reagent (Molecular Research Center,
Cincinnati, OH, USA). One microgram of total RNAwas transcribed to cDNA byMaxima
First Strand cDNA Synthesis Kit (ThermoFisher, Waltham, MA, USA). Specific
oligonucleotide primers were designed for the Mc1r gene (XM_006222790). Primer sets
were MC1R_fwd 5′-TGCACCTCTTGCTCATCGTT-3′ and MC1R_rvs 5′-
ACCTCCTTGAGTGTCATGCG-3′. The predicted length of PCR product was 160 bps.
Primers for b-actin were used as internal controls (NM_031144). Primer sets were
ACT_fwd 5′-TACTCTGTGTGGATTGGTGGC-3′ and ACT_rvs 5′-GGTGTAAAACGCAG
CTCAGTAA-3′. The predicted length of PCR product was 150 bps. PCR was performed
with FIREPol DNA polymerase (Solis BioDyne, Tartu, Estonia) in T100 thermal cycler
(BioRad, Hercules, CA, USA). After initial heat inactivation (95 C for 3 min) the
following cycling conditions were applied: melting 94 C for 15 s, annealing 50 C for 15 s,
polimerization 72 C for 20 s (35 cycles). After a final 5 min extension at 72 C PCR
products were analyzed on 3% MetaPhor agarose gel (Cambrex BioScience, Rockland,
ME, USA) and fragments were verified by capillary DNA sequencing.
Measurement of cell viability: real-time cell electronic sensing
and MTT assay
Real-time cell electronic sensing is an impedance-based, label-free technique for dynamic
monitoring of living adherent cells, including barrier forming epithelial and brain
endothelial cells (Kiss et al., 2014; Le´na´rt et al., 2015). The RTCA-SP instrument (ACEA
Biosciences, San Diego, CA, USA) registers the impedance of cells in every 10 min and for
each time point cell index is calculated as (Rn - Rb)/15, where Rn is the cell-electrode
impedance of the well when it contains cells and Rb is the background impedance of the
well with the medium alone. E-plates, special 96-well plates with built in gold electrodes,
were coated with collagen type IV and fibronectin for brain endothelial cells at room
temperature and dried for 20 min under UVand air-flow. For background measurements
culture medium (60 ml) was added to each well, then 50 ml of rat brain endothelial cell
suspension was distributed at a cell density of 5  103 cells/well. After cells reached a
steady growth phase they were treated with a-MSH and cytokines.
In parallel we also used an endpoint colorimetric cell viability assay (Kiss et al., 2014).
The yellow 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) dye
is converted by viable cells to purple formazan crystals. Brain endothelial cells were
grown in 96-well plates coated with collagen type IV and fibronectin. After treatment
of confluent monolayers, cells were incubated with 0.5 mg/ml MTT solution in cell
culture medium for 3 h in CO2 incubator. Formazan crystals were dissolved in dimethyl
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sulfoxide, and dye concentration was determined by absorbance measurement at 570 nm
with a multiwell plate reader (Fluostar Optima; BMG Labtechnologies, Offenburg,
Germany).
Measurement of permeability for marker molecules
Penetration of fluorescein isothiocyanate-labeled dextran (FITC-dextran, MW: 4.4 kDa)
and Evans blue-labeled albumin (EBA, MW: 67 kDa) across the BBB model was
determined in permeability studies (Veszelka et al., 2007). Rat brain endothelial cells
co-cultured with pericytes and glia on cell culture inserts were treated with cytokines
and/or a-MSH for 1 h. After treatment inserts were transferred to 12-well plates
containing 1.5 ml Ringer-HEPES buffer (150 mM NaCl, 2.2 mM CaCl2, 0.2 mM MgCl2,
5.2 mM KCl, 6 mM NaHCO3, 5 mM glucose, and 10 mM HEPES, pH 7.4) in the lower
compartments. In the upper compartments culture medium was replaced by 500 ml
Ringer-HEPES buffer containing EBA complex (1 mg/ml bovine serum albumin and
167.5 mg/ml Evans blue) and FITC-dextran (100 mg/ml). The plates were kept for 30 min
on a rocking platform (100 rpm) at 37 C in an incubator with 5% CO2. After the
incubation the concentrations of the marker molecules in samples from the upper and
lower compartments were determined by a fluorescence multiwell plate reader (Fluostar
Optima; BMG Labtechnologies, Offenburg, Germany; excitation wavelength: 485 nm,
emission wavelength: 520 nm for FITC-dextran; excitation wavelength: 584 nm, emission
wavelength: 680 nm for EBA). The apparent permeability coefficients (Papp) were
calculated by the following equation (Va´radi et al., 2017):
Papp ¼ C½ B  VB
A C½ A  t
(1)
where [C]B is the concentration of the tracer in the lower (basal) compartment after 1 h,
[C]A is the concentration of the tracer in the upper (apical) compartment at 0 h, VB is the
volume of the basal compartment (1.5 ml) and A is the surface area available for
permeability (1.12 cm2).
Immunohistochemistry
Melanocortin-1 receptor
Isolated rat brain microvessels and brain endothelial cells, co-cultured with brain
pericytes and glial cells, were immunostained for MC1R as we described in our previous
paper for epithelial cells (Va´radi et al., 2017). Cells were washed in PBS, fixed with ice cold
acetone/methanol solution (1:1) for 5 min, and blocked with 3% BSA–PBS for 1 h.
A rabbit anti-human MC1R antibody (M9193; 1 mg/ml) was used as primary antibody
for overnight at 4 C. Incubation with secondary antibody, Alexa Fluor 488 conjugated
goat-anti-rabbit IgG (A11029; ThermoFisher Scientific, Waltham, MA, USA; 2 mg/ml)
and nucleus stain ethidium homodimer-1 (1 mM) lasted for 1 h. The samples were
thoroughly washed with PBS after each step and mounted in Fluoromount-G (Southern
Biotech, Birmingham, AL, USA). Stainings were visualized by a Leica SP5 confocal laser
scanning microscope (Leica Microsystems GmbH, Wetzlar, Germany).
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Junctional proteins and NF-kB p65 subunit
Rat brain endothelial cells treated with cytokines and/or a-MSH for 1 h were fixed and
permeabilized with ice cold acetone/methanol solution (1:1) and blocked in 3% BSA–PBS
for 1 h. Cell were incubated with rabbit anti-rat b-catenin polyclonal (C2206; 1 mg/ml)
or rabbit anti-rat claudin-5 polyclonal (SAB4502981; 1 mg/ml) primary antibodies
overnight, followed by secondary labeling with Cy3-conjugated goat-anti-rabbit IgG
(C2306; 2 mg/ml) and a nucleus stain (H33342; 1 mg/ml) for 1 h. For NF-kB p65 subunit
immunostaining a rabbit anti-human p65 polyclonal antibody (sc-372; Santa Cruz
Biotechnology, Dallas, TX, USA; 100 mg/ml, overnight incubation) was used, followed by
incubation with Alexa Fluor 488-conjugated goat-anti-rabbit IgG (A11029; ThermoFisher
Scientific, Waltham, MA, USA; 2 mg/ml) and H33342 for 1 h. Cells were washed and
mounted as described above. For both TJ protein and NF-kB stainings samples were
observed by a Leica SP5 confocal laser scanning microscope. Images showing TJ staining
were analyzed using MATLAB software (MathWorks, Natick, MA, USA). The
backgrounds of each image were determined and subtracted from the corresponding
image to compensate the occasional non-uniform background. Then, the grayscale images
were converted to binary. Objects with size less than 6 pixels were eliminated to reduce any
false structure. The areas of the structures were determined by the pixel number of the
structures on the binary images. The object number defines the number of the separated,
non-contact structure elements of the images. Images of NF-kB immunostaining were
analyzed using ImageJ software (National Institutes of Health, Rockville, MD, USA) as
described in our previous paper (Sa´ntha et al., 2016).
Measurement of ROS production
Reactive oxygen species production was detected by chloromethyl-dichloro-dihydro-
fluorecein diacetate (DCFDA; Life Technologies, Carlsbad, CA, USA) as we described
previously (Veszelka et al., 2013; Le´na´rt et al., 2015). The indicator penetrates into the cells
and interacts with intracellular esterases. After its oxidation fluorescent molecules are
produced, and the fluorescent signal is proportional to the produced ROS. Confluent
brain endothelial cells were cultured in black 96-well plates with glass bottoms (Corning
Costar, Corning, NY, USA). After 1 h treatment cells were incubated with Ringer-HEPES
buffer containing 2 mM DCFDA for 1 h at 37 C. Hydrogen peroxide (100 mM) was used
as a reference compound (positive control). Fluorescence was measured at 485 nm
excitation and 520 nm emission wavelengths by a Fluostar Optima multiwell plate reader
(BMG Labtechnologies, Offenburg, Germany) every 5 min for 1 h. Fluorescence
intensities are shown in arbitrary units.
Statistical analysis
Statistical analysis was done by GraphPad Prism 5.0 software (GraphPad Software Inc., La
Jolla, CA, USA). Data are presented as mean ± SEM. Comparison of groups was
performed using ANOVA and Dunnett or Bonferroni tests. Differences were considered
significant at P < 0.05.
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RESULTS
Expression of melanocortin-1 receptor on rat brain microvessels
and cultured brain endothelial cells
MC1R gene expression was detected on both freshly isolated rat brain microvessels and
confluent rat brain endothelial cell cultures with reverse transcription followed by PCR
amplification using the specifically designed rat primers (Fig. 1A). This result was
strengthened by immunohistochemistry for MC1R. The brain endothelial staining
(Fig. 1B) was similar to the apical surface staining of MC1R on Caco-2 cells in our
previous work (Va´radi et al., 2017). Positive MC1R immunostaining was found on freshly
isolated brain microvessels, too (Fig. 1C).
Effect of a-MSH on rat brain endothelial cell metabolism
and viability
Treatment of rat brain endothelial cells with a-MSH peptide alone (1 pM to 1 mM) did
not have any significant effect on cell kinetics measured by impedance, indicating good
cell viability, attachment and barrier integrity. Followed by real-time cell electronic
sensing the cells showed no change after a-MSH treatment, the kinetic curves ran
similarly to the untreated control samples (Fig. 2A). In addition, the colorimetric
MTT assay also did not detect any metabolic change in cells after 24 h treatment with
a-MSH as compared to control (Fig. 2B). For further experiments 1 and 10 pM
concentrations of a-MSH were selected, which correspond to the physiological range
of the neurohormone in the blood (Kova´cs et al., 2001; Magnoni et al., 2003).
Effect of a-MSH on cytokine treated rat brain endothelial barrier
integrity: real-time cell kinetics
To determine the treatment concentrations of TNF-a and IL-1b to induce brain
endothelial damage, four different combinations of cytokine concentrations
(10 + 10, 10 + 25, 25 + 25, 50 + 25 ng/ml) were tested (Fig. 3A). The cytokine combination
in the tested concentration range decreased brain endothelial viability. There were no
statistically significant differences between the four cytokine treatment groups. For further
experiments the smallest, 10 + 10 ng/ml concentrations of the cytokines were selected.
Treatment of rat brain endothelial cells with TNF-a and IL-1b decreased the cell index
by more than 50% at 6 h time point which further dropped by 24 h (Fig. 3B). Low
concentration of a-MSH (1 pM) significantly protected against the cytokine-induced cell
viability decrease (Fig. 3C). There was no statistically significant difference between
the two cytokine + a-MSH treatment groups.
Effect of a-MSH on cytokine treated rat brain endothelial barrier
integrity: permeability for marker molecules
The integrity of brain endothelial monolayers was tested by its permeability for marker
molecules. A low permeability for both FITC-dextran (1.91 ± 0.02  10-6 cm/s) and large
biomolecule albumin (0.88 ± 0.13 10-6 cm/s) was measured on the triple co-culture model
of the BBB. Cytokine treatment significantly increased the permeability of the co-cultures
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Figure 1 Melanocortin-1 receptor (MC1R) expression on rat brain endothelial cells and isolated rat
brain microvessels. (A) Cells were grown in culture dish and brain microvessels were isolated from adult
rat brain. Total RNAwas extracted, and reverse transcription and PCR amplification were performed for
Mc1r. Actin gene was used as reference. The predicted length of the PCR products was 160 bps. Frag-
ments were analyzed on MetaPhor agarose gel (3%) next low range DNA marker. (B) Cultured brain
endothelial cells were grown on culture inserts and immunostained for MC1R. Cell nuclei were labeled
with ethidium homodimer-1 (red). Green: MC1R labeling. Scale bar: 10 mm. (C) Isolated brain
microvessels were immunostained for MC1R. Fluorescent labeling is shown together with differential
interference contrast to reveal the structure of brain capillary. Cell nuclei were labeled with ethidium
homodimer-1 (red). Green: MC1R labeling. Scale bar: 5 mm. MC1R, melanocortin-1 receptor; RBEC,
rat brain endothelial cells; MV, microvessels. Full-size DOI: 10.7717/peerj.4774/fig-1
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for both markers (Fig. 4). The lower, 1 pM concentration of a-MSH peptide significantly
blocked the barrier opening effect of the cytokines for FITC-dextran and albumin, while 10
pM a-MSH significantly strengthened the cellular barrier for the bigger marker molecule.
Effect of a-MSH on cytokine treated rat brain endothelial barrier integrity:
immunostaining for claudin-5 and b-catenin junctional proteins
Rat brain endothelial cells form tight paracellular barrier, which was visualized by the
localization of integral membrane TJ protein claudin-5 and adherens junction protein
b-catenin (Fig. 5). These junctional proteins appeared in the cell membranes in a
continuous, belt-like manner. In the control, untreated group continuous stainings were
visible without gaps at the cell border. In the cytokine treated group gaps and fragmented
junctional staining (arrowheads, Fig. 5A) and cytoplasmic redistribution of junctional
proteins (asterisks, Fig. 5A) were observed. In cells treated with both a-MSH and cytokine
the staining of TJ proteins was more similar to the control group. The object number
on the immunostained pictures significantly increased due to cytokine treatment as
compared to the control and a-MSH treated group (Figs. 5B and 5C).
Effect of a-MSH on cytokine treated rat brain endothelial cells:
ROS production
Treatment with TNF-a and IL-1b significantly increased ROS production in brain
endothelial cells compared to the basal ROS production of the control group (Fig. 6).
Low concentrations of a-MSH peptide alone did not change the basal ROS production,
while it could statistically significantly decrease the cytokine-induced ROS production in
cultured brain endothelial cells. Hydrogen peroxide treatment was used as a reference
inducer of ROS in the assay, as in our previous study (Veszelka et al., 2013).
0 4 8 12 16 20 24
0.00
0.25
0.50
0.75
1.00
control
TX-100
1 pM α-MSH
10 pM α -MSH
100 pM α-MSH
1 μM α-MSH
10 nM α -MSH
Time
N
o
rm
a
li
z
e
d
 c
e
ll
 i
n
d
e
x
0
25
50
75
100
125
α -MSH
C 1 pM 10 pM 100 pM 10 nM 1 μM TX-100
M
T
T
 a
s
s
a
y
 (
%
 o
f 
c
o
n
tr
o
l)
A B
Figure 2 The effect of different concentrations of a-MSH on the cell viability of rat brain endothelial cells. (A) Cultured brain endothelial cells
were treated with a-MSH (1 pM to 1 mM) for 24 h. Control group received culture medium. Endothelial cells treated with 1% Triton X-100
detergent were used as cytotoxicity control. The cell index followed by impedance did not change after a-MSH treatment. (B) The metabolic
activity of rat brain endothelial cells was measured by MTTassay, which did not detect any alteration caused by a-MSH. Mean ± SEM, n = 4–8. C,
control group; TX-100, Triton X-100. Full-size DOI: 10.7717/peerj.4774/fig-2
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Effect of a-MSH on cytokine-induced NF-kB nuclear translocation
in rat brain endothelial cells
Cytokine treatment induced inflammatory reaction can be measured reliably by the
translocation of the p65 subunit of NF-kB transcriptional factor into cell nuclei. In the
control group the localization of NF-kB p65 is mostly cytoplasmic (Fig. 7A). Treatment
with inflammatory cytokines induced the nuclear translocation of the transcription factor
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Figure 4 The effect of a-MSH treatment on the permeability of cytokine treated triple co-culture
model of the BBB. Brain endothelial cells co-cultured with pericytes and astrocytes on culture inserts
were treated with cytokines (10 ng/ml TNF-a and 10 ng/ml IL-1b) without or with a-MSH (1 or 10 pM)
for 1 h. Then, permeability was measured for 4 kDa FITC-dextran and albumin. Control group received
culture medium. Mean ± SEM, n = 7–17, P < 0.001. Asterisks indicate that groups were compared to
the control group. Pound signs indicate that groups were compared to the cytokine-treated group. C,
control group; CK, cytokine treated group; ns, no significant difference between the two groups.
Full-size DOI: 10.7717/peerj.4774/fig-4
Figure 3 The effect of a-MSH treatment on cell viability of cytokine treated rat brain endothelial
cells. (A) Rat brain endothelial cells were treated with four different combinations of cytokine con-
centrations (TNF-a + IL-1b: 10 + 10, 10 + 25, 25 + 25, and 50 + 25 ng/ml) for 24 h and the cellular
effects were monitored by impedance. Control group received culture medium. (B) Rat brain endothelial
cells were treated with cytokines (10 ng/ml TNF-a and 10 ng/ml IL-1b) without or with a-MSH (1 and
10 pM) and the cellular effects were monitored by impedance for 24 h. Control group received culture
medium. The cytokines decreased the cell index, which effect could be ameliorated by a-MSH treat-
ment, especially by the lower, 1 pM a-MSH concentration. (C) After 24 h treatment the cell viability
significantly decreased due to cytokine treatment, while 1 pM a-MSH significantly blocked the cytokine
effect. Mean ± SEM, n = 3–6, P < 0.001, #P < 0.05. Asterisks indicate that groups were compared to
the control group. Pound signs indicate that groups were compared to the cytokine-treated group. C,
control group; CK, cytokine treated group. Full-size DOI: 10.7717/peerj.4774/fig-3
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Figure 5 The effect of a-MSH treatment on the immunostaining of tight junction proteins claudin-5 and b-catenin in cytokine treated rat
brain endothelial cells. (A) Rat brain endothelial cells were treated with cytokines (10 ng/ml TNF-a and 10 ng/ml IL-1b) without or with 1 pM
a-MSH for 1 h and stained for tight junction proteins claudin-5 and b-catenin. The control group received culture medium. The fluorescent
microscopy images demonstrate the expression and organization of the junctional proteins. Cytokine treatment significantly increased the number
of gaps and intracellular redistribution compared to the control and a-MSH treated group. Arrowheads: gaps and fragmented junctional staining;
asterisks: cytoplasmic redistribution of junctional proteins. Scale bar: 10 mm. (B) The object number on the claudin-5 immunostained pictures was
quantified by MATLAB software. (C) The object number on the b-catenin immunostained pictures was quantified by MATLAB software. Mean ±
SEM, n = 4, P < 0.05, #P < 0.05. : CK compared to C; #: CK +MSH compared to CK. C, control group; CK, cytokine treated group; a-MSH + CK,
a-MSH, and cytokine treated group. Full-size DOI: 10.7717/peerj.4774/fig-5
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in rat brain endothelial cells (Fig. 7). This NF-kB nuclear translocation, which was also
quantified based on the fluorescent intensity of the immunostainings, was inhibited
by a-MSH at 1 pM concentration (Fig. 7A), and which was the most effective in other
experiments.
DISCUSSION
The proper function of the BBB is crucial for CNS homeostasis and BBB dysfunction
can be both the cause and consequence of neuronal injury (Stanimirovic & Friedman,
2012; Zhao et al., 2015; Liebner et al., 2018). The neuroprotective effects of a-MSH
were already investigated in different in vivo experimental models (Catania, 2008),
but there are no data related to the BBB. Based on our recent study, in which a-MSH
reduced cytokine-induced barrier dysfunction in human intestinal epithelial cells
(Va´radi et al., 2017), we hypothesized a protective effect of this neurohormone on
brain endothelial cells.
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Figure 6 The effect of a-MSH treatment on the reactive oxygen species production in cytokine
treated rat brain endothelial cells. Rat brain endothelial cells were treated with cytokines (10 ng/ml
TNF-a and 10 ng/ml IL-1b) without or with 1 or 10 pM a-MSH for 1 h. Cells were also treated with 1 or
10 pM a-MSH alone. Control group received culture medium. Mean ± SEM, n = 4–8. C, control group;
CK, cytokine treated group; H2O2, hydrogen peroxide treated group (100 mM).
P < 0.01, P < 0.001,
#P < 0.05, ###P < 0.001. Asterisks indicate that groups were compared to the control group. Pound signs
indicate that groups were compared to the cytokine-treated group. C, control group; CK, cytokine
treated group; a-MSH+CK, a-MSH and cytokine treated group.
Full-size DOI: 10.7717/peerj.4774/fig-6
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MC1R participates in the mediation of the anti-inflammatory action of a-MSH in
both the CNS and the periphery (Brzoska et al., 2008). We demonstrated for the first
time the expression of MC1R, the main receptor of a-MSH, on isolated rat brain
microvessels and cultured brain endothelial cells both at the mRNA and protein level
(Fig. 1). MC1R is expressed not only in the CNS but also in peripheral tissues (Brzoska
et al., 2008), including human intestinal epithelial cells (Va´radi et al., 2017). Our findings
are in agreement with the presence of a-MSH binding sites on cultured mouse brain
endothelial cells (de Angelis et al., 1995).
We tested the effect of a-MSH on rat brain endothelial cells in a wide range of
concentrations, from 1 pM to 1 mM, and found no change in the cell kinetics indicating
undisturbed cell function and monolayer integrity (Fig. 2). The physiological
concentration of a-MSH is low in both human plasma (6 pM; Magnoni et al., 2003)
and newborn pig plasma samples (30 pM; Kova´cs et al., 2001). The level of a-MSH
changes in pathological conditions: in our previous study asphyxia and reperfusion
increased the level of a-MSH in the plasma, but decreased it in the cerebrospinal fluid of
newborn pigs (Kova´cs et al., 2001). The neuropeptide in the blood is secreted from the
pituitary, while a-MSH in the cerebrospinal fluid is derived from the CNS, explaining the
Figure 7 Immunohistochemical staining and analysis of NF-kB activation in cytokine- and a-MSH-treated brain endothelial cells. (A) Rat
brain endothelial cells were treated with culture medium, cytokines (10 ng/ml TNF-a and 10 ng/ml IL-1b), or cytokines and 1 pM a-MSH. Nuclear
localization of the NF-kB p65 subunit was monitored by immunostaining. Cell nuclei were labeled with Hoechst 33342. Green: p65 staining;
blue: cell nuclei. Scale bar: 25 mm. (B) Fluorescence intensity of the NF-kB immunostaining in cell nuclei and cytoplasm. Mean ± SEM, n = 20–28,
P < 0.05, #P < 0.05. : CK, CK +MSH compared to C; #: CK +MSH compared to CK. C, control group; CK, cytokine treated group; a-MSH + CK,
a-MSH and cytokine treated group. Full-size DOI: 10.7717/peerj.4774/fig-7
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discordant regulation of the neuropeptide in these two compartments (de Rotte, Bouman
& van Wimersma Greidanus, 1980). A low permeability for intravenously injected a-MSH
was measured across the BBB in rats (Wilson, 1988), indicating the absence of an active
transport. At pathologically high or pharmacological concentrations a-MSH crosses the
BBB contributing to the brain levels (de Rotte, Bouman & van Wimersma Greidanus, 1980;
Banks & Kastin, 1995).
To mimic inflammatory conditions, a combination of TNF-a and IL-1b was selected
to induce barrier dysfunction on the BBB model, similarly to our previous study on
cultured intestinal epithelial cells (Va´radi et al., 2017). Brain endothelial cells were more
sensitive to cytokine treatment, lower concentrations were already effective to induce
enhanced permeability as compared to epithelial cells (Va´radi et al., 2017). Pro-
inflammatory cytokines are linked to increased permeability in brain endothelial cell
cultures (Deli et al., 1995; Didier et al., 2003; Lopez-Ramirez et al., 2012). As expected,
TNF-a and IL-1b decreased the impedance of the cell layers (Fig. 3) and elevated the
permeability for marker molecules dextran and albumin on the BBB model (Fig. 4),
indicating a barrier leakage, which was inhibited by a-MSH. The same barrier protective
effect was found on intestinal epithelial cells, too (Va´radi et al., 2017). Treatment with
a-MSH in physiological concentrations did not modify the basal permeability of the
BBB model. Previous studies in rats also found that a-MSH at low concentrations did not
alter BBB permeability for albumin (Sankar, Domer & Kastin, 1981) or a small anion
(Kastin & Fabre, 1982).
The cytokine-induced disruption of rat brain endothelial cell layers was also reflected at
the level of cell–cell interactions. In concordance with the functional measurements of
barrier opening, cytokine treatment caused a discontinuous immunostaining at cellular
borders, and cytoplasmic redistribution for claudin-5 and b-catenin (Fig. 5). The
fragmented staining at the intercellular junctions and the increased presence of the
junctional proteins in the cytoplasm of brain endothelial cells were reflected by the
elevated object number on the immunostained culture samples. In our recent work
we also demonstrated morphological changes at cellular junctions in parallel with opening
of the barrier by TJ modulator peptides in a BBB model (Bocsik et al., 2016). Elevated
TNF-a and IL-1b expression, disruption of TJ proteins and increased BBB permeability
were also found in mice treated with an environmental toxicant and nanoparticles
(Zhang et al., 2012). The direct link between these events was proven in two independent
works. NF-kB response elements were identified in the promoter region of claudin-5 gene,
and TNF-a treatment significantly reduced the promoter activity and the transcription
of claudin-5 in both brain and myocardial endothelial cells (Burek & Fo¨rster, 2009).
TNF-a treatment repressed claudin-5 promoter activity in mouse brain endothelial cell
cultures via NF-kB signaling and p65 overexpression (Aslam et al., 2012). In addition
to claudin-5, the decrease of MARVELD-2, another TJ protein was also induced by
pro-inflammatory cytokine treatment in human brain endothelial cells (Lopez-Ramirez
et al., 2013).
Oxidative stress is one of the main mechanisms of neuronal toxicity in inflammation
(Sochocka, Diniz & Leszek, 2017). ROS are also central in increased BBB permeability
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induced by cytokines (Rochfort & Cummins, 2015), or by amyloid-b peptide (Veszelka
et al., 2013). We also measured elevated ROS production after cytokine treatment in brain
endothelial cells, which was inhibited by a-MSH (Fig. 6). While no data are available
on BBB models, suppression of ROS production and oxidative stress as an important
element of the anti-inflammatory effect of a-MSH were demonstrated on other cell types
(Brzoska et al., 2008).
Translocation of the NF-kB p65 subunit into cell nuclei is a key event in inflammatory
reactions in the CNS (Catania, 2008). The canonical NF-kB pathway can be induced
by both TNF-a and IL-1b and lead to the transcription of genes, like cyclooxigenase-2,
nitric oxide synthase, inflammatory cytokines, and matrix metalloproteinases (Pires et al.,
2018), which participate in BBB dysfunction and opening (Rosenberg, 2012). The
nuclear translocation of NF-kB was described in peripheral endothelial cells induced by
TNF-a or IL-1b (Mako´ et al., 2010), as well as in brain endothelial cell inflammatory
pathway (Lee et al., 2001). We confirmed in our study that cytokine treatment induced
NF-kB nuclear translocation in brain endothelial cells, and proved that a-MSH can
inhibit this effect (Fig. 7), similarly to our recent findings on epithelial cells (Va´radi et al.,
2017). Since NF-kB signaling in TNF-a treated brain endothelial cells can directly
decrease claudin-5 expression (Burek & Fo¨rster, 2009; Aslam et al., 2012), this signaling
pathway can mediate, at least partially, the protective effect of a-MSH on barrier integrity.
Our data are supported by another study where a-MSH blocked adhesion molecule
expression by NF-kB inhibition in cytokine treated human dermal microvascular
endothelial cells (Kalden et al., 1999). These results further strengthen the role of
a-MSH as a potent anti-inflammatory molecule which exerts its effect by inhibition
of the NF-kB transcription factor.
In conclusion, the direct protective effect of a-MSH on pro-inflammatory cytokine-
induced barrier dysfunction and inflammatory activation in rat brain endothelial cell
cultures was investigated for the first time in this study. We demonstrated the presence
of the major a-MSH receptor MC1R on brain endothelial cells, and a protective effect
of the anti-inflammatory hormone on cytokine-induced barrier opening in parallel
with the inhibition of NF-kB nuclear translocation in a BBB model. These findings
support the beneficial effect of a-MSH to restore BBB integrity in inflammatory
conditions.
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